Document Detail

Comparative study of mitoxantrone efficacy profile in patients with relapsing--remitting and secondary progressive multiple sclerosis.
MedLine Citation:
PMID:  20810516     Owner:  NLM     Status:  In-Data-Review    
Background: Mitoxantrone (MTX) is an immunosuppressive drug approved for multiple sclerosis (MS) treatment. Objective: The aim of this study is to evaluate and to compare the clinical and neuroradiological responses to MTX in relapsing-remitting (RR) and secondary progressive (SP) MS patients. Methods: We conducted a retrospective, non-randomized, open-label, observational study to evaluate the clinical and neuroradiological response to the drug in 79 patients with RR MS and 210 patients with SP MS. Results: A statistically significant reduction (p < 0.001) in the number of relapses was observed during MTX treatment and in the year after in both RR and SP MS patients. On the contrary, an opposite behavior in terms of disease progression was found in RR compared with SP MS patients, resulting in a statistically significant improvement of the Expanded Disability Status Scale score during the MTX treatment (p < 0.001) and in the year after (p < 0.001) for RR MS patients compared with a continuous, although mild, worsening of the disability in SP MS patients (p < 0.001). Finally, a significant reduction (p < 0.001) of new Gd-enhanced lesions in both RR and SP MS patients was observed in a subgroup of 224 individuals who underwent a brain MRI evaluation before and after MTX treatment. Conclusions: MTX should be considered as an effective therapeutic option in RR MS patients with evidence of relevant disease activity, but the potential life-threatening adverse events and the overall benefit-risk ratio must be carefully evaluated at individual patient level.
Federica Esposito; Marta Radaelli; Vittorio Martinelli; Maria Pia Sormani; Filippo Martinelli Boneschi; Lucia Moiola; Maria Assunta Rocca; Mariaemma Rodegher; Giancarlo Comi
Related Documents :
17659556 - Upper cervical spinal cord cross-sectional area in relapsing remitting multiple scleros...
18814986 - Whole-body t2* mapping at 1.5 t.
16987836 - Vasoactive therapies in systemic sclerosis.
19456306 - Sweating impairment in patients with multiple sclerosis.
9105096 - Circulating il-1ra and il-10 levels are increased but do not predict the development of...
4279816 - The relief of bone pain in primary biliary cirrhosis with calcium infusions.
Publication Detail:
Type:  Journal Article     Date:  2010-09-01
Journal Detail:
Title:  Multiple sclerosis (Houndmills, Basingstoke, England)     Volume:  16     ISSN:  1477-0970     ISO Abbreviation:  Mult. Scler.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-12-01     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9509185     Medline TA:  Mult Scler     Country:  England    
Other Details:
Languages:  eng     Pagination:  1490-9     Citation Subset:  IM    
Department of Neurology, Division of Neuroscience, Scientific Institute San Raffaele, Milan, Italy/Institute of Experimental Neurology, Scientific Institute San Raffaele, Milan, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Early predictors of juvenile sacroiliitis in enthesitis-related arthritis.
Next Document:  Assessing changes in relapse rates in multiple sclerosis.